Molecular modeling evaluation of the binding effect of five protease inhibitors to COVID-19 main protease
Chem Phys. 2021 Feb 1;542:111080. doi: 10.1016/j.chemphys.2020.111080. Epub 2020 Dec 11.ABSTRACTCoronavirus disease 2019 (COVID-19) has caused more than 840,000 deaths as of 31 August 2020 in the whole world. The COVID-19 main protease (Mpro) has been validated as an attractive target for drug design. In this work, the binding mechanisms of five protease inhibitors (e.g., danoprevir, darunavir, ASC09, lopinavir and ritonavir) to COVID-19 Mpro were investigated. Based on the docking score, five protease inhibitors structures were selected for further evaluation. It is found that most of the selected drug molecules bind stab...
Source: Chemical Physics - February 1, 2021 Category: Chemistry Authors: Jian Liu You Zhai Lijun Liang Danyan Zhu Qingwei Zhao Yunqing Qiu Source Type: news

Molecular modeling evaluation of the binding effect of five protease inhibitors to COVID-19 main protease
Chem Phys. 2021 Feb 1;542:111080. doi: 10.1016/j.chemphys.2020.111080. Epub 2020 Dec 11.ABSTRACTCoronavirus disease 2019 (COVID-19) has caused more than 840,000 deaths as of 31 August 2020 in the whole world. The COVID-19 main protease (Mpro) has been validated as an attractive target for drug design. In this work, the binding mechanisms of five protease inhibitors (e.g., danoprevir, darunavir, ASC09, lopinavir and ritonavir) to COVID-19 Mpro were investigated. Based on the docking score, five protease inhibitors structures were selected for further evaluation. It is found that most of the selected drug molecules bind stab...
Source: Chemical Physics - February 1, 2021 Category: Chemistry Authors: Jian Liu You Zhai Lijun Liang Danyan Zhu Qingwei Zhao Yunqing Qiu Source Type: news

Molecular modeling evaluation of the binding effect of five protease inhibitors to COVID-19 main protease
Chem Phys. 2021 Feb 1;542:111080. doi: 10.1016/j.chemphys.2020.111080. Epub 2020 Dec 11.ABSTRACTCoronavirus disease 2019 (COVID-19) has caused more than 840,000 deaths as of 31 August 2020 in the whole world. The COVID-19 main protease (Mpro) has been validated as an attractive target for drug design. In this work, the binding mechanisms of five protease inhibitors (e.g., danoprevir, darunavir, ASC09, lopinavir and ritonavir) to COVID-19 Mpro were investigated. Based on the docking score, five protease inhibitors structures were selected for further evaluation. It is found that most of the selected drug molecules bind stab...
Source: Chemical Physics - February 1, 2021 Category: Chemistry Authors: Jian Liu You Zhai Lijun Liang Danyan Zhu Qingwei Zhao Yunqing Qiu Source Type: news

Molecular modeling evaluation of the binding effect of five protease inhibitors to COVID-19 main protease
Chem Phys. 2021 Feb 1;542:111080. doi: 10.1016/j.chemphys.2020.111080. Epub 2020 Dec 11.ABSTRACTCoronavirus disease 2019 (COVID-19) has caused more than 840,000 deaths as of 31 August 2020 in the whole world. The COVID-19 main protease (Mpro) has been validated as an attractive target for drug design. In this work, the binding mechanisms of five protease inhibitors (e.g., danoprevir, darunavir, ASC09, lopinavir and ritonavir) to COVID-19 Mpro were investigated. Based on the docking score, five protease inhibitors structures were selected for further evaluation. It is found that most of the selected drug molecules bind stab...
Source: Chemical Physics - February 1, 2021 Category: Chemistry Authors: Jian Liu You Zhai Lijun Liang Danyan Zhu Qingwei Zhao Yunqing Qiu Source Type: news

Molecular modeling evaluation of the binding effect of five protease inhibitors to COVID-19 main protease
Chem Phys. 2021 Feb 1;542:111080. doi: 10.1016/j.chemphys.2020.111080. Epub 2020 Dec 11.ABSTRACTCoronavirus disease 2019 (COVID-19) has caused more than 840,000 deaths as of 31 August 2020 in the whole world. The COVID-19 main protease (Mpro) has been validated as an attractive target for drug design. In this work, the binding mechanisms of five protease inhibitors (e.g., danoprevir, darunavir, ASC09, lopinavir and ritonavir) to COVID-19 Mpro were investigated. Based on the docking score, five protease inhibitors structures were selected for further evaluation. It is found that most of the selected drug molecules bind stab...
Source: Chemical Physics - February 1, 2021 Category: Chemistry Authors: Jian Liu You Zhai Lijun Liang Danyan Zhu Qingwei Zhao Yunqing Qiu Source Type: news

Molecular modeling evaluation of the binding effect of five protease inhibitors to COVID-19 main protease
Chem Phys. 2021 Feb 1;542:111080. doi: 10.1016/j.chemphys.2020.111080. Epub 2020 Dec 11.ABSTRACTCoronavirus disease 2019 (COVID-19) has caused more than 840,000 deaths as of 31 August 2020 in the whole world. The COVID-19 main protease (Mpro) has been validated as an attractive target for drug design. In this work, the binding mechanisms of five protease inhibitors (e.g., danoprevir, darunavir, ASC09, lopinavir and ritonavir) to COVID-19 Mpro were investigated. Based on the docking score, five protease inhibitors structures were selected for further evaluation. It is found that most of the selected drug molecules bind stab...
Source: Chemical Physics - February 1, 2021 Category: Chemistry Authors: Jian Liu You Zhai Lijun Liang Danyan Zhu Qingwei Zhao Yunqing Qiu Source Type: news

Molecular modeling evaluation of the binding effect of five protease inhibitors to COVID-19 main protease
Chem Phys. 2021 Feb 1;542:111080. doi: 10.1016/j.chemphys.2020.111080. Epub 2020 Dec 11.ABSTRACTCoronavirus disease 2019 (COVID-19) has caused more than 840,000 deaths as of 31 August 2020 in the whole world. The COVID-19 main protease (Mpro) has been validated as an attractive target for drug design. In this work, the binding mechanisms of five protease inhibitors (e.g., danoprevir, darunavir, ASC09, lopinavir and ritonavir) to COVID-19 Mpro were investigated. Based on the docking score, five protease inhibitors structures were selected for further evaluation. It is found that most of the selected drug molecules bind stab...
Source: Chemical Physics - February 1, 2021 Category: Chemistry Authors: Jian Liu You Zhai Lijun Liang Danyan Zhu Qingwei Zhao Yunqing Qiu Source Type: news

Molecular modeling evaluation of the binding effect of five protease inhibitors to COVID-19 main protease
Chem Phys. 2021 Feb 1;542:111080. doi: 10.1016/j.chemphys.2020.111080. Epub 2020 Dec 11.ABSTRACTCoronavirus disease 2019 (COVID-19) has caused more than 840,000 deaths as of 31 August 2020 in the whole world. The COVID-19 main protease (Mpro) has been validated as an attractive target for drug design. In this work, the binding mechanisms of five protease inhibitors (e.g., danoprevir, darunavir, ASC09, lopinavir and ritonavir) to COVID-19 Mpro were investigated. Based on the docking score, five protease inhibitors structures were selected for further evaluation. It is found that most of the selected drug molecules bind stab...
Source: Chemical Physics - February 1, 2021 Category: Chemistry Authors: Jian Liu You Zhai Lijun Liang Danyan Zhu Qingwei Zhao Yunqing Qiu Source Type: news

Molecular modeling evaluation of the binding effect of five protease inhibitors to COVID-19 main protease
Chem Phys. 2021 Feb 1;542:111080. doi: 10.1016/j.chemphys.2020.111080. Epub 2020 Dec 11.ABSTRACTCoronavirus disease 2019 (COVID-19) has caused more than 840,000 deaths as of 31 August 2020 in the whole world. The COVID-19 main protease (Mpro) has been validated as an attractive target for drug design. In this work, the binding mechanisms of five protease inhibitors (e.g., danoprevir, darunavir, ASC09, lopinavir and ritonavir) to COVID-19 Mpro were investigated. Based on the docking score, five protease inhibitors structures were selected for further evaluation. It is found that most of the selected drug molecules bind stab...
Source: Chemical Physics - February 1, 2021 Category: Chemistry Authors: Jian Liu You Zhai Lijun Liang Danyan Zhu Qingwei Zhao Yunqing Qiu Source Type: news

Molecular modeling evaluation of the binding effect of five protease inhibitors to COVID-19 main protease
Chem Phys. 2021 Feb 1;542:111080. doi: 10.1016/j.chemphys.2020.111080. Epub 2020 Dec 11.ABSTRACTCoronavirus disease 2019 (COVID-19) has caused more than 840,000 deaths as of 31 August 2020 in the whole world. The COVID-19 main protease (Mpro) has been validated as an attractive target for drug design. In this work, the binding mechanisms of five protease inhibitors (e.g., danoprevir, darunavir, ASC09, lopinavir and ritonavir) to COVID-19 Mpro were investigated. Based on the docking score, five protease inhibitors structures were selected for further evaluation. It is found that most of the selected drug molecules bind stab...
Source: Chemical Physics - February 1, 2021 Category: Chemistry Authors: Jian Liu You Zhai Lijun Liang Danyan Zhu Qingwei Zhao Yunqing Qiu Source Type: news

Molecular modeling evaluation of the binding effect of five protease inhibitors to COVID-19 main protease
Chem Phys. 2021 Feb 1;542:111080. doi: 10.1016/j.chemphys.2020.111080. Epub 2020 Dec 11.ABSTRACTCoronavirus disease 2019 (COVID-19) has caused more than 840,000 deaths as of 31 August 2020 in the whole world. The COVID-19 main protease (Mpro) has been validated as an attractive target for drug design. In this work, the binding mechanisms of five protease inhibitors (e.g., danoprevir, darunavir, ASC09, lopinavir and ritonavir) to COVID-19 Mpro were investigated. Based on the docking score, five protease inhibitors structures were selected for further evaluation. It is found that most of the selected drug molecules bind stab...
Source: Chemical Physics - February 1, 2021 Category: Chemistry Authors: Jian Liu You Zhai Lijun Liang Danyan Zhu Qingwei Zhao Yunqing Qiu Source Type: news

Molecular modeling evaluation of the binding effect of five protease inhibitors to COVID-19 main protease
Chem Phys. 2021 Feb 1;542:111080. doi: 10.1016/j.chemphys.2020.111080. Epub 2020 Dec 11.ABSTRACTCoronavirus disease 2019 (COVID-19) has caused more than 840,000 deaths as of 31 August 2020 in the whole world. The COVID-19 main protease (Mpro) has been validated as an attractive target for drug design. In this work, the binding mechanisms of five protease inhibitors (e.g., danoprevir, darunavir, ASC09, lopinavir and ritonavir) to COVID-19 Mpro were investigated. Based on the docking score, five protease inhibitors structures were selected for further evaluation. It is found that most of the selected drug molecules bind stab...
Source: Chemical Physics - February 1, 2021 Category: Chemistry Authors: Jian Liu You Zhai Lijun Liang Danyan Zhu Qingwei Zhao Yunqing Qiu Source Type: news

Molecular modeling evaluation of the binding effect of five protease inhibitors to COVID-19 main protease
Chem Phys. 2021 Feb 1;542:111080. doi: 10.1016/j.chemphys.2020.111080. Epub 2020 Dec 11.ABSTRACTCoronavirus disease 2019 (COVID-19) has caused more than 840,000 deaths as of 31 August 2020 in the whole world. The COVID-19 main protease (Mpro) has been validated as an attractive target for drug design. In this work, the binding mechanisms of five protease inhibitors (e.g., danoprevir, darunavir, ASC09, lopinavir and ritonavir) to COVID-19 Mpro were investigated. Based on the docking score, five protease inhibitors structures were selected for further evaluation. It is found that most of the selected drug molecules bind stab...
Source: Chemical Physics - February 1, 2021 Category: Chemistry Authors: Jian Liu You Zhai Lijun Liang Danyan Zhu Qingwei Zhao Yunqing Qiu Source Type: news

Molecular modeling evaluation of the binding effect of five protease inhibitors to COVID-19 main protease
Chem Phys. 2021 Feb 1;542:111080. doi: 10.1016/j.chemphys.2020.111080. Epub 2020 Dec 11.ABSTRACTCoronavirus disease 2019 (COVID-19) has caused more than 840,000 deaths as of 31 August 2020 in the whole world. The COVID-19 main protease (Mpro) has been validated as an attractive target for drug design. In this work, the binding mechanisms of five protease inhibitors (e.g., danoprevir, darunavir, ASC09, lopinavir and ritonavir) to COVID-19 Mpro were investigated. Based on the docking score, five protease inhibitors structures were selected for further evaluation. It is found that most of the selected drug molecules bind stab...
Source: Chemical Physics - February 1, 2021 Category: Chemistry Authors: Jian Liu You Zhai Lijun Liang Danyan Zhu Qingwei Zhao Yunqing Qiu Source Type: news

Molecular modeling evaluation of the binding effect of five protease inhibitors to COVID-19 main protease
Chem Phys. 2021 Feb 1;542:111080. doi: 10.1016/j.chemphys.2020.111080. Epub 2020 Dec 11.ABSTRACTCoronavirus disease 2019 (COVID-19) has caused more than 840,000 deaths as of 31 August 2020 in the whole world. The COVID-19 main protease (Mpro) has been validated as an attractive target for drug design. In this work, the binding mechanisms of five protease inhibitors (e.g., danoprevir, darunavir, ASC09, lopinavir and ritonavir) to COVID-19 Mpro were investigated. Based on the docking score, five protease inhibitors structures were selected for further evaluation. It is found that most of the selected drug molecules bind stab...
Source: Chemical Physics - February 1, 2021 Category: Chemistry Authors: Jian Liu You Zhai Lijun Liang Danyan Zhu Qingwei Zhao Yunqing Qiu Source Type: news

Molecular modeling evaluation of the binding effect of five protease inhibitors to COVID-19 main protease
Chem Phys. 2021 Feb 1;542:111080. doi: 10.1016/j.chemphys.2020.111080. Epub 2020 Dec 11.ABSTRACTCoronavirus disease 2019 (COVID-19) has caused more than 840,000 deaths as of 31 August 2020 in the whole world. The COVID-19 main protease (Mpro) has been validated as an attractive target for drug design. In this work, the binding mechanisms of five protease inhibitors (e.g., danoprevir, darunavir, ASC09, lopinavir and ritonavir) to COVID-19 Mpro were investigated. Based on the docking score, five protease inhibitors structures were selected for further evaluation. It is found that most of the selected drug molecules bind stab...
Source: Chemical Physics - February 1, 2021 Category: Chemistry Authors: Jian Liu You Zhai Lijun Liang Danyan Zhu Qingwei Zhao Yunqing Qiu Source Type: news

Molecular modeling evaluation of the binding effect of five protease inhibitors to COVID-19 main protease
Chem Phys. 2021 Feb 1;542:111080. doi: 10.1016/j.chemphys.2020.111080. Epub 2020 Dec 11.ABSTRACTCoronavirus disease 2019 (COVID-19) has caused more than 840,000 deaths as of 31 August 2020 in the whole world. The COVID-19 main protease (Mpro) has been validated as an attractive target for drug design. In this work, the binding mechanisms of five protease inhibitors (e.g., danoprevir, darunavir, ASC09, lopinavir and ritonavir) to COVID-19 Mpro were investigated. Based on the docking score, five protease inhibitors structures were selected for further evaluation. It is found that most of the selected drug molecules bind stab...
Source: Chemical Physics - February 1, 2021 Category: Chemistry Authors: Jian Liu You Zhai Lijun Liang Danyan Zhu Qingwei Zhao Yunqing Qiu Source Type: news

Molecular modeling evaluation of the binding effect of five protease inhibitors to COVID-19 main protease
Chem Phys. 2021 Feb 1;542:111080. doi: 10.1016/j.chemphys.2020.111080. Epub 2020 Dec 11.ABSTRACTCoronavirus disease 2019 (COVID-19) has caused more than 840,000 deaths as of 31 August 2020 in the whole world. The COVID-19 main protease (Mpro) has been validated as an attractive target for drug design. In this work, the binding mechanisms of five protease inhibitors (e.g., danoprevir, darunavir, ASC09, lopinavir and ritonavir) to COVID-19 Mpro were investigated. Based on the docking score, five protease inhibitors structures were selected for further evaluation. It is found that most of the selected drug molecules bind stab...
Source: Chemical Physics - February 1, 2021 Category: Chemistry Authors: Jian Liu You Zhai Lijun Liang Danyan Zhu Qingwei Zhao Yunqing Qiu Source Type: news

Molecular modeling evaluation of the binding effect of five protease inhibitors to COVID-19 main protease
Chem Phys. 2021 Feb 1;542:111080. doi: 10.1016/j.chemphys.2020.111080. Epub 2020 Dec 11.ABSTRACTCoronavirus disease 2019 (COVID-19) has caused more than 840,000 deaths as of 31 August 2020 in the whole world. The COVID-19 main protease (Mpro) has been validated as an attractive target for drug design. In this work, the binding mechanisms of five protease inhibitors (e.g., danoprevir, darunavir, ASC09, lopinavir and ritonavir) to COVID-19 Mpro were investigated. Based on the docking score, five protease inhibitors structures were selected for further evaluation. It is found that most of the selected drug molecules bind stab...
Source: Chemical Physics - February 1, 2021 Category: Chemistry Authors: Jian Liu You Zhai Lijun Liang Danyan Zhu Qingwei Zhao Yunqing Qiu Source Type: news

Molecular modeling evaluation of the binding effect of five protease inhibitors to COVID-19 main protease
Chem Phys. 2021 Feb 1;542:111080. doi: 10.1016/j.chemphys.2020.111080. Epub 2020 Dec 11.ABSTRACTCoronavirus disease 2019 (COVID-19) has caused more than 840,000 deaths as of 31 August 2020 in the whole world. The COVID-19 main protease (Mpro) has been validated as an attractive target for drug design. In this work, the binding mechanisms of five protease inhibitors (e.g., danoprevir, darunavir, ASC09, lopinavir and ritonavir) to COVID-19 Mpro were investigated. Based on the docking score, five protease inhibitors structures were selected for further evaluation. It is found that most of the selected drug molecules bind stab...
Source: Chemical Physics - February 1, 2021 Category: Chemistry Authors: Jian Liu You Zhai Lijun Liang Danyan Zhu Qingwei Zhao Yunqing Qiu Source Type: news

Molecular modeling evaluation of the binding effect of five protease inhibitors to COVID-19 main protease
Chem Phys. 2021 Feb 1;542:111080. doi: 10.1016/j.chemphys.2020.111080. Epub 2020 Dec 11.ABSTRACTCoronavirus disease 2019 (COVID-19) has caused more than 840,000 deaths as of 31 August 2020 in the whole world. The COVID-19 main protease (Mpro) has been validated as an attractive target for drug design. In this work, the binding mechanisms of five protease inhibitors (e.g., danoprevir, darunavir, ASC09, lopinavir and ritonavir) to COVID-19 Mpro were investigated. Based on the docking score, five protease inhibitors structures were selected for further evaluation. It is found that most of the selected drug molecules bind stab...
Source: Chemical Physics - February 1, 2021 Category: Chemistry Authors: Jian Liu You Zhai Lijun Liang Danyan Zhu Qingwei Zhao Yunqing Qiu Source Type: news

Molecular modeling evaluation of the binding effect of five protease inhibitors to COVID-19 main protease
Chem Phys. 2021 Feb 1;542:111080. doi: 10.1016/j.chemphys.2020.111080. Epub 2020 Dec 11.ABSTRACTCoronavirus disease 2019 (COVID-19) has caused more than 840,000 deaths as of 31 August 2020 in the whole world. The COVID-19 main protease (Mpro) has been validated as an attractive target for drug design. In this work, the binding mechanisms of five protease inhibitors (e.g., danoprevir, darunavir, ASC09, lopinavir and ritonavir) to COVID-19 Mpro were investigated. Based on the docking score, five protease inhibitors structures were selected for further evaluation. It is found that most of the selected drug molecules bind stab...
Source: Chemical Physics - February 1, 2021 Category: Chemistry Authors: Jian Liu You Zhai Lijun Liang Danyan Zhu Qingwei Zhao Yunqing Qiu Source Type: news

Molecular modeling evaluation of the binding effect of five protease inhibitors to COVID-19 main protease
Chem Phys. 2021 Feb 1;542:111080. doi: 10.1016/j.chemphys.2020.111080. Epub 2020 Dec 11.ABSTRACTCoronavirus disease 2019 (COVID-19) has caused more than 840,000 deaths as of 31 August 2020 in the whole world. The COVID-19 main protease (Mpro) has been validated as an attractive target for drug design. In this work, the binding mechanisms of five protease inhibitors (e.g., danoprevir, darunavir, ASC09, lopinavir and ritonavir) to COVID-19 Mpro were investigated. Based on the docking score, five protease inhibitors structures were selected for further evaluation. It is found that most of the selected drug molecules bind stab...
Source: Chemical Physics - February 1, 2021 Category: Chemistry Authors: Jian Liu You Zhai Lijun Liang Danyan Zhu Qingwei Zhao Yunqing Qiu Source Type: news

Molecular modeling evaluation of the binding effect of five protease inhibitors to COVID-19 main protease
Chem Phys. 2021 Feb 1;542:111080. doi: 10.1016/j.chemphys.2020.111080. Epub 2020 Dec 11.ABSTRACTCoronavirus disease 2019 (COVID-19) has caused more than 840,000 deaths as of 31 August 2020 in the whole world. The COVID-19 main protease (Mpro) has been validated as an attractive target for drug design. In this work, the binding mechanisms of five protease inhibitors (e.g., danoprevir, darunavir, ASC09, lopinavir and ritonavir) to COVID-19 Mpro were investigated. Based on the docking score, five protease inhibitors structures were selected for further evaluation. It is found that most of the selected drug molecules bind stab...
Source: Chemical Physics - February 1, 2021 Category: Chemistry Authors: Jian Liu You Zhai Lijun Liang Danyan Zhu Qingwei Zhao Yunqing Qiu Source Type: news

Molecular modeling evaluation of the binding effect of five protease inhibitors to COVID-19 main protease
Chem Phys. 2021 Feb 1;542:111080. doi: 10.1016/j.chemphys.2020.111080. Epub 2020 Dec 11.ABSTRACTCoronavirus disease 2019 (COVID-19) has caused more than 840,000 deaths as of 31 August 2020 in the whole world. The COVID-19 main protease (Mpro) has been validated as an attractive target for drug design. In this work, the binding mechanisms of five protease inhibitors (e.g., danoprevir, darunavir, ASC09, lopinavir and ritonavir) to COVID-19 Mpro were investigated. Based on the docking score, five protease inhibitors structures were selected for further evaluation. It is found that most of the selected drug molecules bind stab...
Source: Chemical Physics - February 1, 2021 Category: Chemistry Authors: Jian Liu You Zhai Lijun Liang Danyan Zhu Qingwei Zhao Yunqing Qiu Source Type: news

Molecular modeling evaluation of the binding effect of five protease inhibitors to COVID-19 main protease.
Abstract Coronavirus disease 2019 (COVID-19) has caused more than 840,000 deaths as of 31 August 2020 in the whole world. The COVID-19 main protease (Mpro) has been validated as an attractive target for drug design. In this work, the binding mechanisms of five protease inhibitors (e.g., danoprevir, darunavir, ASC09, lopinavir and ritonavir) to COVID-19 Mpro were investigated. Based on the docking score, five protease inhibitors structures were selected for further evaluation. It is found that most of the selected drug molecules bind stably to the COVID-19 Mpro from the molecular dynamics simulation. Moreover, the ...
Source: Chemical Physics - February 1, 2021 Category: Chemistry Authors: Liu J, Zhai Y, Liang L, Zhu D, Zhao Q, Qiu Y Tags: Chem Phys Source Type: news

Comunicado de la FDA sobre la seguridad de los medicamentos: Informaci & oacute;n actualizada sobre la interacci & oacute;n entre el medicamento Victrelis (boceprevir) y ciertos medicamentos reforzados inhibidores de la proteasa del VIH
El 26 de abril del 2012, la Administraci ón de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en inglés) informó al público que, en estos momentos, no se recomienda tomar conjuntamente Victrelis (boceprevir), un inhibidor de la proteasa del virus de la hepatitis C (VHC) junto con ciertos inhibidores de la proteasa del virus de la inmunodeficiencia humana VIH reforzados con ritonavir, por la posibilidad de reducir la eficacia de los medicamentos, lo que puede desencadenar el aumento del VHC o VIH en la sangre (carga viral). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 6, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

WHO publishes updated living guideline on therapeutics and Covid-19, WHO
Based on the results of a systematic review and meta-analysis, the guideline panel makes new strong recommendations against the use of hydroxychloroquine and lopinavir/ritonavir in patients with Covid-19, regardless of disease severity. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - December 21, 2020 Category: Consumer Health News Source Type: news

Lopinavir-Ritonavir Does Not Improve COVID-19 Outcomes Lopinavir-Ritonavir Does Not Improve COVID-19 Outcomes
Lopinavir-ritonavir is not associated with improved outcomes in patients hospitalized with COVID-19, a new trial shows.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - October 14, 2020 Category: Intensive Care Tags: Infectious Diseases News Source Type: news

Lopinavir - Ritonavir No Benefit in Patients Admitted With COVID - 19
No reductions seen in 28 - day mortality or duration of hospital stay in COVID - 19 with lopinavir - ritonavir (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - October 7, 2020 Category: Respiratory Medicine Tags: Infections, Nursing, Pharmacy, Pulmonology, Critical Care, Emergency Medicine, Journal, Source Type: news

Lopinavir-Ritonavir No Benefit in Patients Admitted With COVID-19
WEDNESDAY, Oct. 7, 2020 -- Lopinavir-ritonavir is not associated with reductions in 28-day mortality or duration of hospital stay among patients admitted to the hospital with COVID-19, according to a study published online Oct. 5 in The... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 7, 2020 Category: Pharmaceuticals Source Type: news

Lopinavirritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, The Lancet
Summary Background Lopinavir –ritonavir has been proposed as a treatment for COVID-19 on the basis of in vitro activity, preclinical studies, and observational studies. Here, we report the results of a randomised trial to assess whether lopinavir–ritonavir improves outcomes in patients admitted to hospital with COVID-19. M ethods In this randomised, controlled, open-label, platform trial, a range of possible treatments was compared with usual care in patients admitted to hospital with COVID-19. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients were randomly allocated to either u...
Source: Current Awareness Service for Health (CASH) - October 6, 2020 Category: Consumer Health News Source Type: news

HIV drugs lopinavir and ritonavir do NOT work as a Covid-19 treatment or cure, study finds
The Oxford University-led RECOVERY study has published its final results on lopinavir-ritonavir after withdrawing the drug combination from trials in June when medics realised it didn't work. (Source: the Mail online | Health)
Source: the Mail online | Health - October 6, 2020 Category: Consumer Health News Source Type: news

The Lancet: Lopinavir-ritonavir is not an effective treatment for patients hospitalised with COVID-19
(The Lancet) The drug combination lopinavir-ritonavir is not an effective treatment for patients admitted to hospital with COVID-19, according to the results of a randomised controlled trial published in The Lancet. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - October 5, 2020 Category: Infectious Diseases Source Type: news

Coronavirus patient treated with HIV drug saw heart rate drop dangerously low
The patient, in Singapore, was given lopinavir + ritonavir - a drug commonly used in HIV patients because it can stop viruses from being able to reproduce in the body. (Source: the Mail online | Health)
Source: the Mail online | Health - August 24, 2020 Category: Consumer Health News Source Type: news

Lopinavir/Ritonavir COVID-19 Treatment Linked to Bradycardia
FRIDAY, July 17, 2020 -- Lopinavir/ritonavir (LPV/RTV) treatment of COVID-19 is associated with an increased risk for bradycardia, according to a study published online July 9 in Circulation: Arrhythmia and Electrophysiology. Christophe Beyls,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 17, 2020 Category: Pharmaceuticals Source Type: news

WHO Halts Hydroxychloroquine, HIV Drugs in COVID Trials After Failure to Reduce Death WHO Halts Hydroxychloroquine, HIV Drugs in COVID Trials After Failure to Reduce Death
WHO said on Saturday that it was discontinuing its trials of the malaria drug hydroxychloroquine and combination HIV drug lopinavir/ritonavir in hospitalised patients with COVID-19 after they failed to reduce mortality.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - July 7, 2020 Category: Infectious Diseases Tags: Infectious Diseases News Source Type: news

WHO ending hydroxycholorquine trial for COVID
WHO says a review of the interim results showed hydroxychloroquine and lopinavir/ritonavir "produce little or no reduction in the mortality of hospitalized COVID-19 patients when compared to standard of care." (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 4, 2020 Category: Pharmaceuticals Source Type: news

WHO says trials show malaria and HIV drugs don't cut Covid-19 hospital deaths
Hydroxychloroquine and lopinavir/ritonavir not found to help patients in hospitalCoronavirus – latest updatesSee all our coronavirus coverageThe World Health Organization (WHO) said on Saturday that it was discontinuing its trials of the malaria drughydroxychloroquine and combination HIV drug lopinavir/ritonavir for patients in hospital with Covid-19 after they failed to reduce mortality.The setback came as WHO also reported more than 200,000 new cases globally of the disease for the first time in a single day. The US accounted for 53,213 of the total 212,326 new cases recorded on Friday, the WHO said.Continue readin...
Source: Guardian Unlimited Science - July 4, 2020 Category: Science Authors: Reuters Tags: Coronavirus outbreak Medical research World Health Organization World news US news Pharmaceuticals industry Science Infectious diseases Source Type: news

Preliminary trial results find antiviral drug lopinavir/ritonavir does not reduce death in hospitalised patients with COVID-19
The‘RECOVERY’ trial has released preliminary results showing lopinavir/ritonavir, an antiviral drug commonly used to treat HIV, had no significant mortality benefit in hospitalised COVID-19 patients. (Source: Medical Research Council General News)
Source: Medical Research Council General News - July 1, 2020 Category: Research Source Type: news

Antiviral hyped as potential Covid treatment "ineffective", finds major study
Lopinavir-ritonavir showed “no beneficial effect” in hospitalised patients not on ventilators, as per University of Oxford’s Recovery trial – the world’s largest randomised clinical trial of potential Covid treatments. “The data convincingly rule out any meaningful mortality benefit of lopinavir-ritonavir in the h ospitalised Covid-19 patients,” it said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 29, 2020 Category: Pharmaceuticals Source Type: news

Covid-19 treatment hopes dashed as trial of promising HIV drug reveals it does NOT work
Oxford University scientists pulled lopinavir/ritonavir from the RECOVERY Trial today after results showed it had no benefit on people hospitalised with the virus. (Source: the Mail online | Health)
Source: the Mail online | Health - June 29, 2020 Category: Consumer Health News Source Type: news

WHO Says Looking at Interim Trial Data on HIV Drugs to Treat COVID-19 WHO Says Looking at Interim Trial Data on HIV Drugs to Treat COVID-19
Large multi-country trials of the combination HIV drug lopinavir/ritonavir to treat COVID-19 have recruited thousands of patients and WHO is now looking at interim data, the UN agency's chief scientist said on Thursday.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - June 19, 2020 Category: Intensive Care Tags: Infectious Diseases News Source Type: news

WHO testing interim data from COVID-19 trial on HIV drugs
The World Health Organization is looking at interim data from its large multi-country trial of the combination of HIV drugs Lopinavir and Ritonavir to treat COVID-19 patients, the UN agency's chief scientist Soumya Swaminathan said on Thursday. (Source: Reuters: Health)
Source: Reuters: Health - June 18, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

U.K. Researchers Say They Have Found First Drug that Improves COVID-19 Survival
Researchers in England say they have the first evidence that a drug can improve COVID-19 survival: A steroid called dexamethasone reduced deaths by up to one third in severely ill hospitalized patients. Results were announced Tuesday and researchers said they would publish them soon. The study is a large, strict test that randomly assigned 2,104 patients to get the drug and compared them with 4,321 patients getting only usual care. The drug was given either orally or through an IV. It reduced deaths by 35% in patients who needed treatment with breathing machines and by 20% in those only needing supplemental oxygen. It did ...
Source: TIME: Science - June 16, 2020 Category: Science Authors: MARILYNN MARCHIONE /AP Tags: Uncategorized Source Type: news

The Curious Case of Covid-19 in Africa
Eunice G. Kamwendo is an Economist and Strategic Advisor with UNDP Africa in New York. Chaltu Daniel Kalbessa is a UNDP Fellow and Strategic Analyst with UNDP Africa in New York.By Eunice G. Kamwendo and Chaltu Daniel KalbessaNEW YORK, Jun 3 2020 (IPS) With very weak health systems and overall capacity constraints to effectively respond to the deadly coronavirus disease, Africa’s fate against the invisible enemy, was going to be nothing short of catastrophic according to early predictions. Although Africa is yet to reach its peak, many countries are not seeing the exponential growth in case numbers, or in mortality r...
Source: IPS Inter Press Service - Health - June 3, 2020 Category: International Medicine & Public Health Authors: Eunice G. Kamwendo and Chaltu Daniel Kalbessa Tags: Africa Aid Headlines Health Humanitarian Emergencies TerraViva United Nations Source Type: news

Nigeria: What Was Learned in Review of Country's First 32 COVID-19 Cases
[Premium Times] Almost 97 per cent of the first set of COVID-19 patients in Lagos State were treated with lopinavir-ritonavir with no recorded death, a new report has shown. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - May 20, 2020 Category: African Health Source Type: news

Long-term Safety and Efficacy of OBV/PTV/r + DSV in HCV Long-term Safety and Efficacy of OBV/PTV/r + DSV in HCV
This study reports on the long-term liver disease-associated outcomes for a DAA regimen consisting of ombitasvir/paritaprevir/ritonavir plus dasabuvir +/- ribavirin for the treatment of chronic HCV.Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 14, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

India to test four drugs as part of WHO trial
Potential anti-viral agents remdesivir, chloroquine/hydroxychloroquine, lopinavir-ritonavir and lopinavir-ritonavir with interferon will be evaluated as part of the trial, the Indian Council of Medical Research said on Wednesday. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 13, 2020 Category: Pharmaceuticals Source Type: news

India to test four drugs for Covid-19 as part of the WHO solidarity trial
On Wednesday the Indian Council of Medical Research (ICMR) announced that potential anti-viral agents, Remdesivir, Chloroquine/Hydroxychloroquine, Lopinavir-Ritonavir and Lopinavir-Ritonavir with Interferon ( ß1a) will be evaluated as part of the solidarity trial. (Source: The Economic Times)
Source: The Economic Times - May 12, 2020 Category: Consumer Health News Source Type: news